Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at Hard-to-Treat cancers

NCT ID NCT07250386

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a new treatment called CEA-targeted CAR-T cells in people with advanced non-small cell lung cancer or breast cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells that carry a protein called CEA. The main goals are to check safety and find the best dose, while also seeing if the treatment can shrink tumors or slow disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310017, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact